45 results about "Immature cells" patented technology

This invention provides an isolated electrophysiologically immature cell or its derivative that has been modified to provide a mature electrophysiological phenotype and populations of these cells. Compositions containing these cells and populations of cells are also provided by this invention. These cells and compositions have therapeutic and diagnostic uses. Non-limiting therapeutic uses include regenerating cardiac tissue, improving cardiac function, restoring action potential of cardiac tissue; and treating or preventing cardiac malfunction. The cells and population of cells also can be used diagnostically to screen drug or other therapeutic candidate.

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt / Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt / Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

The present invention provides methods and compositions of engineered cells for use in the continuous or transient delivery of growth factors and angiogenesis modulating agents, such as vascular endothelial growth factor (VEGF), in conjunction with constructs for replacing or augmenting organ functions. In one aspect of the invention, the genetically engineered cells can be immature cells that are capable of differentiating and assimilating into the target region. The methods of the present invention can be used to enhance vascularization locally at a target site in need of repair, growth, or implantation through the incorporation of autologous cells which have been genetically engineered to secrete a growth factor or angiogenesis modulating agent.

The invention discloses a DC cell based on SP17 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SP17 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention relates to a technical process for synthesizing a camptothecin sugar derivative by artificially inducing nothapodytes nimmoniana (graham) mablerley endophyte. The process disclosed by the invention comprises the following steps of: charging immature cells of nothapodytes nimmoniana (graham) mablerley into an amplification culture medium according to the proportion of inoculation amount of 50-200g / L wet weight and culturing at 25-30 DEG C; adding 1-2,000 mummol / L of combined elicitor and 20-50g / L of sugar in the exponential growth initial period of the cells; adding a saccharified reagent and catalyst for carrying out saccharification reaction; and adding 1-2,000 mummol / L of combined elicitor for inducing in the exponential growth metaphase of the cells. The method disclosed by the invention realizes the synthesis of the camptothecin derivative in an artificial inducing way by utilizing the characteristics of the endophyte of the nothapodytes nimmoniana (graham) mablerley which is the camptothecin producing plant and cansolve the problems of lower conversion rate, high technical requirement on strain culture, more separating steps, and the like existing in the traditional biosynthesis methods and provide reference for the research of camptothecin as well as the anticancer effect and anticancer medicines thereof.

The invention discloses a DC cell based on P53 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by P53 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a DC cell based on BCG1 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by BCG1 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention provides a traditional Chinese medicine composition for treating acute myeloblastic leukemia (AML) M1. The composition is prepared from the following components: 15-25g of radix rehmanniae, 8-16g of cortex moutan, 4-8g of honey-fried liquorice, 18-32g of oldenlandia diffusa, 14-20g of lalang grass rhizome, 18-28g of glossy privet fruit, 14-28g of herba cistanche, 4-8g of cordyceps sinensis, 15-25g of folium isatidis, 8-16g of wild radix ophiopogonis and 8-16g of honeysuckle. The medicine provided by the invention has the following functions: pertinently treating specific AML-M1, selectively inhibiting and killing immature cells, inducing leukemia cell apoptosis and having stronger pertinence and higher treatment effect; promoting differentiation and maturity of leukemia cells; regulating qi and blood and enhancing immunity; promoting recovery of normal hematopoietic function of marrows; and reducing reversion and preventing medicine resistance.

The invention discloses a traditional Chinese medicine combination for treating acute granulocyte AML-M4 leukemia, comprising the following compositions: 15-25g of root of rehmannia, 8-16g of tree peony bark, 4-8g of fired powder liquorice with honey, 18-32g of Ophiorrhiza pumila, 14-20g of rhizoma imperatae, 18-28g of ligustrum lucidum, 14-28g of herba cistanche, 4-8g of aweto, 12-24g of brown lily, 10-20g of radix patriniae heterophylla and 11-21g of smilax glabra. The medicament treats concrete AML-M4 acute granulocytic leukemia with pertinence, selectively inhibits and kills immature cells, induces apoptosis of leukemia cells, has stronger pertinence and higher curative effect and has the effects of promoting differentiation and maturation of the leukemia cells, regulating qi and blood, strengthening the immunologic function, promoting recovery of marrow normal hematopoietic function, reducing reversion, preventing production of drug resistance, reducing the toxic and side effects of chemotherapy and improving the physique.